7th Annual MarketsandMarkets Biomarker and Companion Diagnostics Conference

3rd - 4th February, 2022 | San Diego
CONFERENCE SPEAKERS
Advisors
John Rossi
John Rossi
Director, Translational Sciences ,
Kite Pharma


John joined Kite in February 2015 and is currently a Senior Director in the Department of Translational Medicine. John leads the Cell Therapy Clinical Pharmacology group and also supports or leads biomarker activities related to clinical development of Kite’s CAR T-cell pipeline. At Kite, John has led the development of a biomarker strategy and has also built an effective translational team to support the clinical development of axicabtagene ciloleucel/KTE-C19 and KTE-X19. During this time, John’s team has contributed directly to the US and European approval of axicabtagene ciloleucel through pharmacokinetic and pharmacodynamic evaluation of this product. Among many achievements at Kite, John has represented Kite through external scientific presentations and collaborative manuscripts with leading academic researchers such as Dr. Steven Rosenberg and Dr. James Kochenderfer at the National Cancer Institute. Scientific accomplishments include the discovery of novel metrics to characterize CAR T cells based on their functionality, novel biomarker knowledge of how CAR T cells work in the clinic, mechanistic information on CAR-related toxicities, novel insights into the biology of the tumor immune microenvironment, including immune checkpoints, and the pivotal role of IL-15 in the context of CAR T-cell function.


Speakers
John Rossi
John Rossi
Director, Translational Sciences ,
Kite Pharma


John joined Kite in February 2015 and is currently a Senior Director in the Department of Translational Medicine. John leads the Cell Therapy Clinical Pharmacology group and also supports or leads biomarker activities related to clinical development of Kite’s CAR T-cell pipeline. At Kite, John has led the development of a biomarker strategy and has also built an effective translational team to support the clinical development of axicabtagene ciloleucel/KTE-C19 and KTE-X19. During this time, John’s team has contributed directly to the US and European approval of axicabtagene ciloleucel through pharmacokinetic and pharmacodynamic evaluation of this product. Among many achievements at Kite, John has represented Kite through external scientific presentations and collaborative manuscripts with leading academic researchers such as Dr. Steven Rosenberg and Dr. James Kochenderfer at the National Cancer Institute. Scientific accomplishments include the discovery of novel metrics to characterize CAR T cells based on their functionality, novel biomarker knowledge of how CAR T cells work in the clinic, mechanistic information on CAR-related toxicities, novel insights into the biology of the tumor immune microenvironment, including immune checkpoints, and the pivotal role of IL-15 in the context of CAR T-cell function.


Mike Baratta
Mike Baratta
Scientific Director, Translational Biomarker Research ,
Takeda


Mike Baratta currently serves as a Scientific Director for the Clinical Biomarker Innovation and Development group at Takeda Pharmaceuticals in Cambridge, MA. He received his B.A. from Loyola University of Chicago and a Masters Certificate in Applied Healthcare Project Management from Villanova University. Mike began his career as a member of the Global Drug Metabolism group at Pharmacia/G.D. Searle and transitioned to a Principal Scientist role with Pfizer after the closure of the merger. Prior to joining Takeda in 2013, he served as a Director on Nonclinical Development, Pharmacokinetics and Biometrics with Duck Flats Pharma. Mike is a member of several FNIH biomarker consortia, industry committees and serves as a standing member of the NIH/NSD-B grant application reviewer.  Mikes research focus is mass spectrometry focused analytical assay development and clinical validation of post translation biomarkers supporting patient characterization/stratification strategies. 

 


Yisrael Katz
Yisrael Katz
Director of Clinical Applications,
Calviri Inc.


Dr. Katz is a board-certified internal medicine physician and director of clinical applications for Calviri, Inc. In this role, Dr. Katz has been instrumental in setting up early-phase clinical trials for FAST Vaccines (Frameshift Antigens for Specific Therapy), for multiple indications including pediatric brainstem tumors as well as adult head/neck and non-small cell lung cancers. Dr. Katz’s medical training was completed at Georgetown University Hospital; he continues to practice inpatient hospital medicine at the University of California – San Diego. He is also the founder of Clinical Strategy, LLC, and is a nationally-recognized clinical educator, having taught at over twenty US medical schools. Dr. Katz’s background in translational research includes previous work in biochemistry and neuroimaging, ongoing drug discovery work for neurodegenerative disease at the University of Pennsylvania, and oncology diagnostics and therapeutics at Calviri and the Biodesign Institute in Arizona. 


Naveen Babbar
Naveen Babbar
Executive Director, Precision Medicine Leader,
Novartis


Naveen Babbar, Ph.D., is currently a Precision Medicine Leader at Novartis Oncology. Before joining Novartis in 2014, Naveen led product development teams at multiple diagnostic companies, including Genmark Diagnostics. Naveen holds a Doctorate from the University of Arizona and a Postdoctoral fellowships from Sidney Kimmel Cancer Center at Johns Hopkins.


 Hedieh Saffari
Hedieh Saffari
Biomarker Clinical Assay Lead, Manager,
Pfizer



Zheng Feng
Zheng Feng
Head, Molecular Biomarkers & Genomics,
EMD Serono



Christos Patriotis
Christos Patriotis
Program Director, Breast and GYN Cancers, and Bioinformatics,
NCI, NIH



Shilpi Mahajan
Shilpi Mahajan
Senior Scientist, Clinical Pharmacology and Quantitative Pharmacology,
AstraZeneca



Partha Das
Partha Das
Medical Director, Oncology CDx and Biomarkers,
Amgen



Mike Nerenberg
Mike Nerenberg
Senior Vice President, Medical & Clinical Affairs,
Curative



 Paul Kassner
Paul Kassner
Senior Vice President, Quantitative & Computational Biology ,
RAPT Therapeutics



Philip Measor
Philip Measor
Assistant Professor,
Whitworth University